SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 994 participants.
Also called NCT05345327
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 994 participants
- Registry
-
NCT05345327
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Australia, Sri Lanka
- Registry status
- Recruiting
Technical summary
Registry record NCT05345327. Randomized; quadruple masking; primary purpose prevention. Start 2023-01-01 (actual); primary completion 2026-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes
- Acronym
- START
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Metformin
- Lead sponsor
- The George Institute
- Collaborator
- The University of New South Wales
- Collaborator
- Monash University
- Collaborator
- University of Sydney
Record details
- Record id
cardio:ct-nct05345327- Content hash
393a37ad8f950602cc2196756ad72b1bed2a3240da2a2c6be7ef66618fc7135f